New database reveals how many people living with hepatitis C (HCV) are getting the care they need

The BC Hepatitis Testers Cohort (BC-HTC), believed to be one of the most powerful HCV databases in the world, contains anonymized independent medical records health records of 1.5 million patients over 25 years. The database reveals how many people living with HCV are getting the care they need. Although national-level data on actual engagement in HCV care is not yet available, what is seen in the BC data provides a snapshot of what is also likely occurring in Canada overall.

Surveillance cascade Aug 29 11 am - wider for webpage 300 dpi

[Download higher resolution image]

Related Resources

The HCV Illness & Care Journey (HCV ICJ)

View the HCV ICJ: key journey points for people at-risk or diagnosed with hepatitis C and resources that go with each stage of care.

BCMJ Feb 2015 article image2

The BC-HTC database was created by researchers from the University of British Columbia and the BC Centre for Disease Control (BCCDC) to better measure health outcomes and to assess the effectiveness and impact of various treatments and services.

Using this data, the BC-HTC team recently published a paper that included engagement in care data for six HCV cascade of care stages:

1) estimated population prevalence,
2) HCV diagnosed,
3) HCV RNA tested,
4) genotyped,
5) initiated treatment, and
6) achieved sustained virologic response (SVR).

In their paper, the BC-HTC team reported that of those tested and living with chronic HCV, only 32% were receiving liver-related monitoring and 13% were not engaged in any care [1].

The recent availability of highly effective and well-tolerable drugs is considered a major medical breakthrough; however, the cost of these drugs is a concern impacting its uptake, calling for a system to monitor infection and the uptake of treatment and cure.

In Canada, about 210,000 to 460,000 people have HCV, but as many as 20-40% are unaware of their infection [2-3]. Even though HCV incidence is declining, sub-optimal levels of engagement in care may be contributing to the fact that morbidity and mortality related to chronic HCV infection are increasing [4-6]. Patients not engaged across the HCV Illness and Care Journey (HCV ICJ) may face substantial liver damage and other complications including cirrhosis, liver failure, liver cancer, and premature death [7].

For further information or other provider resources see:


1. Janjua, N.Z., et al., The Population Level Cascade of Care for Hepatitis C in British Columbia, Canada: The BC Hepatitis Testers Cohort (BC-HTC). EBioMedicine, 2016. 0(0).

2. Trubnikov, M., P. Yan, and C. Archibald, Estimated prevalence of Hepatitis C virus infection in Canada, 2011. CCDR, 2014. 40(19): p. 429-42.

3. Amin, J., et al., HIV and hepatitis C coinfection within the CAESAR study. HIV Medicine, 2004. 5(3): p. 174-179.

4. Kuo, M., et al., Decreasing Hepatitis C Incidence Among a Population With Repeated Tests: British Columbia, Canada, 1993-2011. Am J Public Health, 2015. 105(8): p. 1604-10.

5. Yu, A., et al., Mortality among British Columbians testing for hepatitis C antibody. BMC Public Health, 2013. 13: p. 291.

6. Krajden, M., et al., Hepatitis C Virus (HCV) Mortality Patterns in the British Columbia Hepatitis Testers Cohort (BC-HTC), in The Liver Meeting 2015, The American Association for the Study of Liver Diseases (AASLD) San Francisco.

7. Public Health Agency of Canada. Hepatitis C: Get the facts. 2015 March 2, 2015; Available from: